Myeloproliferative neoplasm

Study Shows Metformin May Reduce Risk of Blood Cancer

A recent study reveals that the diabetes drug metformin may reduce the risk of blood cancer, specifically myeloproliferative neoplasm (MPN). Apart from its primary function, metformin has shown potential in lowering the risk of colorectal, breast, and prostate cancers, as well as cancer-related death. The drug’s benefits also include anti-aging effects, weight loss, improved fertility in individuals with PCOS, and potential cardiovascular health enhancements.